Tremelimumab

(Imjudo®)

Imjudo®

Drug updated on 11/15/2023

Dosage FormInjection (intravenous; 25 mg/1.25 mL (20 mg/mL), 300 mg/15 mL (20 mg/mL))
Drug ClassCytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) in combination with durvalumab.